«These events offer several venues and platforms to share the exciting progress ViaCyte is making in developing
novel cell replacement therapies for diabetes,» said Paul Laikind, PhD, President and CEO of ViaCyte.
Not exact matches
Other researchers at Joslin are conducting large scale genetic screening for
novel therapeutic targets to control autoimmunity, which will complement the effort of BAIRT to extend autologous beta
cell replacement to patients with type 1 diabetes.
Our group is specifically working on improvement of islet isolation and transplantation protocols in clinical practice and the development of
novel therapeutic options in the field of beta
cell replacement with a clear translational «bench to bedside» approach by linking experimental research with preclinical and clinical work:
The new iPS
cells generated using
novel methods may represent biomedically - and clinically - ideal
cells, providing potential platforms for studying human disease mechanisms and achieving the long - term goal of personalized
cell -
replacement therapy.
San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a
novel islet
cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.